EXPRESSION AND CLINICAL SIGNIFICANCE OF ADAM17 AND EGFR IN ENDOMETRIAL CARCINOMA

Abstract

Abstract: Objective: To investigate the expression and clinical significance of adisintegrin and metalloprotease-17 (ADAM17) and epidermal growth factor receptor(EGFR) in endometrial carcinoma. Methods: Immunohistochemical staining was used to detect the ADAM17 and EGFR expression in 20 cases of normal endometrium, 20 cases of atypical hyperplasia endometrium and 50 cases of endometrial carcinoma. Results: The positive expression rate of ADAM17 and EGFR in endometrial carcinoma were all obviously higher than normal endometrium and atypical hyperplasia endometrium (P<0.01). In endometrial carcinoma, the expression of ADAM17 and EGFR were related to muscular infiltration depth and lymph node metastasis (P<0.05), but not related to age and whether menopause (P>0.05). In endometrial carcinoma, the expression of ADAM17 was positively correlated to EGFR (r=0.691, P<0.01). Conclusions: ADAM17 and EGFR may play important role in development and metastasis of endometrial carcinoma.

Key words: Endometrial carcinoma, ADAM17, EGFR, Immunohistochemistry

摘要： 目的: 探讨子宫内膜癌组织ADAM17、EGFR的表达和临床意义。方法: 应用免疫组化染色法检测20例正常子宫内膜、20例不典型增生子宫内膜和50例子宫内膜癌组织ADAM17和EGFR的表达情况。结果: 子宫内膜癌组织ADAM17、EGFR的阳性表达率均明显高于正常子宫内膜和不典型增生子宫内膜（P<0.01）;子宫内膜癌组织ADAM17、EGFR表达与肌层浸润深度和淋巴结转移有关（P<0.05）,与年龄、是否绝经无关（P>0.05）;子宫内膜癌组织ADAM17与EGFR的表达呈正相关关系（r=0.691,P<0.01）。结论: ADAM17、EGFR在子宫内膜癌的发生发展和转移过程中可能起重要作用。

关键词: 子宫内膜癌, ADAM17, EGFR, 免疫组织化学

CLC Number:

R737.33

LIU Xin, XIE Yun-peng, WANG Hai-tao. EXPRESSION AND CLINICAL SIGNIFICANCE OF ADAM17 AND EGFR IN ENDOMETRIAL CARCINOMA[J]. Journal of Chengde Medical University, 2017, 34(4): 273-275.

柳新, 谢云鹏, 王海涛. ADAM17、EGFR在子宫内膜癌组织中的表达及临床意义[J]. 承德医学院学报, 2017, 34(4): 273-275.

References

[1] Kim HJ,Cho A,Yun M,et al.Comparison of FDG PET/CT and MRI in lymph node staging of endometrial cancer[J].Ann Nucl Med,2016,30(2):104-113.
[2] Mochizuki S,Okada Y.ADAMs in cancer cell proliferation and progression[J]. Cancer Sci,2007, 98(5):621-628.
[3] Arvelo F,Cotte C.Metalloproteinases in tumor progression[J].Invest Clin,2006,47(2):185-205.
[4] Borrell-Pages M,Rojo F,Albanell J,et al.TACE is required for the activation of the EGFR by TGF-alpha in tumors[J].Embo J,2003,22(5):1114-1124.
[5] Coussens LM,Fingleton B,Matrisian LM.Matrix metalloproteinase inhibitors and cancer:trials and tribulations[J].Science,2002,295(5564):
2387-2392.
[6] Yarden Y,Pines G.The ERBB network:at last, cancer therapy meets systems biology[J].Nat Rev Cancer,2012,12(8):553-563.
[7] Baselga J.Why the epeidermal growth factor receptor? The rationale for cancer therapy[J]. Oncologist,2002,7 Suppl 4:2-8.
[8] Nakamura JL.The epidermal growth factor receptor in malignant gliomas:pathogenesis and therapeutic implications[J].Expert Opin Ther Targets,2007,11(4):463-472.
[9] Paterson AL, O’Donovan M,Provenzano E,et al. Characterization of the timing and prevalence of receptor tyrosine kinase expression changes in oesophageal carcinogenesis[J]. J Pathol, 2013,230(1):118-128.
[10] Kawaguchi Y,Kono K,Mimura K,et al.Targeting EGFR and Her-2 with cetuximab-and trastuzumab- mediated immunotherapy in oesophageal squamous cell carcinoma[J]. Br J Cancer,2007,97(4): 494-501.
[11] Maretzky T,Evers A,Zhou W,et al.Migration of growth factor-stimulated epithelial and endothelial cells depends on EGFR trans-activation by ADAM17[J].Nat Commun,2011,2:229.
[12] Katakowski M, Jiang F, Zheng X, et al.Tumorigenicity of cortical astrocyte cell line induced by the protease ADAM17[J].Cancer Sci,2009,100(9):1597-1604.